Oncology

News

MSD has another TIGIT programme setback

A phase 3 trial of MSD’s anti-TIGIT antibody vibostolimab and PD-1 inhibitor pembrolizumab has been abandoned after a high rate of discontinuations rendered the study futi

News

NICE backs wider tumour profiling use in early breast cancer

Three tests that can be used to profile tumours in people with breast cancer and predict whether they will respond to chemotherapy have been cleared for wider use by the N

News

Mariana Oncology's chief executive Simon Read

Novartis digs deeper in radiopharma with $1.75bn Mariana buy

Novartis has struck another deal to strengthen its position in radiopharmaceuticals, agreeing to pay $1 billion upfront for radioligand therapy (RLT) developer Mariana Onc

News

Dr Elias Sayour, Chong Zhao and Arnav Barpujari discuss the mRNA cancer vaccine developed at the University of Florida

RNA glioblastoma vaccine shows promise in first human trial

A personalised vaccine for the aggressive and fatal brain cancer glioblastoma has shown encouraging signs of efficacy in its first human trial.

News

Astellas expands Poseida alliance on solid tumour CAR-Ts

Astellas has clearly been impressed with a partnership signed last August with Poseida Therapeutics on the development of cell therapies for solid tumours, as it has just

News

Jacobio plans bid for China’s KRAS market with safety edge

Jacobio Pharma has reported the results of its pivotal Chinese study of KRAS G12C inhibitor glecirasib, with a safety profile that could differentiate it from other drugs

MSD has another TIGIT programme setback

NICE backs wider tumour profiling use in early breast cancer

Novartis digs deeper in radiopharma with $1.75bn Mariana buy

RNA glioblastoma vaccine shows promise in first human trial

Astellas expands Poseida alliance on solid tumour CAR-Ts

Jacobio plans bid for China’s KRAS market with safety edge

CMS aims for broader GLP-1 access via federal programmes

How to meet your physicians where they are online

Oncology

Editor's Picks